Open Orphan plc (ORPH) the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is the world leader in the testing of vaccines and antivirals using human challenge study models, is pleased to announce that Quotient has entered into an exclusive contract with hVIVO to support COVID-19 antibody testing in the UK.
Our award-winning AIM expert discusses how some of 2019’s worst performers could bounce back this year.
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the appointment to the board of David Kelly as an Independent Non-Executive Director.
Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that Admission and dealings in its ordinary shares of 0.1 pence each on AIM and Euronext Growth Dublin will commence at 8.00 a.m. today under the ticker ORPH.